Mark T. J. van Bussel

A first-in-man phase 1 study of the DNA-dependent protein kinase inhibitor peposertib (formerly M3814) in patients with advanced solid tumours

Mark T. J. van Bussel, Ahmad Awada, Maja J.A. de Jonge et al. · British Journal of Cancer · 2020 · 117 citations · Full text

Enzyme linked immunosorbent assay for the quantification of nivolumab and pembrolizumab in human serum and cerebrospinal fluid

Dick Pluim, Willeke Ros, Mark T. J. van Bussel et al. · Journal of Pharmaceutical and Biomedical Analysis · 2018 · 75 citations · Full text

Autoimmune Disease, Medicine, Cerebrospinal Fluid +10

Circulating epithelial tumor cell analysis in CSF in patients with leptomeningeal metastases

Mark T. J. van Bussel, Dick Pluim, Bojana Milojkovic Kerklaan et al. · Neurology · 2020 · 63 citations

Intracranial antitumor responses of nivolumab and ipilimumab: a pharmacodynamic and pharmacokinetic perspective, a scoping systematic review

Mark T. J. van Bussel, Jos H. Beijnen, Dieta Brandsma · BMC Cancer · 2019 · 60 citations · Full text

A Phase Ib/II Study of WNT974 + Encorafenib + Cetuximab in Patients With BRAF<i>V600E</i>-Mutant<i>KRAS</i>Wild-Type Metastatic Colorectal Cancer

Josep Tabernero, Eric Van Cutsem, Elena Garralda et al. · The Oncologist · 2023 · 46 citations · Full text